A recent abstract published in Nature Communications outlines a new, easy-to-use tool that could help guide early treatment discussions for people with mHSPC. In a nutshell, the innovative system ...
Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...
The media frenzy surrounding former President Joe Biden’s metastatic prostate cancer diagnosis last May didn’t faze one Lancaster resident. Doctors and politicians debated whether Biden and his ...
More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...
Study results indicate darolutamide plus ADT significantly improved median rPFS compared with placebo plus ADT in hormone-sensitive prostate cancer, and the risk of radiologic progression or death was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results